Current HER2 testing recommendations and clinical relevance as a predictor of response to targeted therapy

Clinical Breast Cancer

Volumn 15, Issue 3, 2015, Pages 171-180

  Ballinger, Tarah J ^a   Sanders, Melinda E ^b   Abramson, Vandana G ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Fluorescence in situ hybridization; Human epidermal growth factor receptor 2; Immunohistochemistry; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ACCURACY; BREAST CANCER; CANCER PATIENT; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PATHOLOGIST; PHASE 3 CLINICAL TRIAL (TOPIC); POLYSOME; PRACTICE GUIDELINE; REVIEW; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; POLYPLOIDY; PREDICTIVE VALUE; PROCEDURES;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR TARGETED THERAPY; POLYPLOIDY; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84929263565     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.11.009     Document Type: Review

References (71)

1. L. Coussens, T.L. Yang-Feng, and Y.C. Liao Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1985 1132 1139
2. C.R. King, M.H. Kraus, and S.A. Aaronson Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 1985 974 976
3. Y. Yarden Biology of HER2 and its importance in breast cancer Oncology 61 suppl 2 2001 1 13
4. A.C. Wolff, M.E. Hammond, and J.N. Schwartz American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 2007 118 145
5. J.J. Barron, M.J. Cziraky, T. Weisman, and D.G. Hicks HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment Oncologist 14 2009 760 768
6. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
7. H. Yaziji, L.C. Goldstein, and T.S. Barry HER-2 testing in breast cancer using parallel tissue-based methods JAMA 291 2004 1972 1977
8. M.F. Press, L. Bernstein, and P.A. Thomas HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894 2904
9. G. Pauletti, W. Godolphin, M.F. Press, and D.J. Slamon Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 13 1996 63 72
10. T. Akiyama, C. Sudo, H. Ogawara, K. Toyoshima, and T. Yamamoto The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1986 1644 1646
11. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
12. A. Goldhirsch, R.D. Gelber, and M.J. Piccart-Gebhart 2 Years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet 382 2013 1021 1028
13. K.L. Pogue-Geile, C. Kim, and J.H. Jeong Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31 J Natl Cancer Inst 105 2013 1782 1788
14. E.A. Perez, E.H. Romond, and V.J. Suman Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 2011 3366 3373
15. A.C. Wolff, M.E. Hammond, and D.G. Hicks Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 2013 3997 4013
16. J.S. Ross, E.A. Slodkowska, W.F. Symmans, L. Pusztai, P.M. Ravdin, and G.N. Hortobagyi The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 2009 320 368
17. S.L. Meijer, J. Wesseling, and V.T. Smit HER2 gene amplification in patients with breast cancer with equivocal IHC results J Clin Pathol 64 2011 1069 1072
18. M. Dowsett, J. Bartlett, and I.O. Ellis Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres J Pathol 199 2003 418 423
19. Hanna WM, Barnes PJ, Chang MC, et al. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. J Clin Oncol Epub 2014 Nov 10.
20. M.F. Press, R.S. Finn, and D. Cameron HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer Clin Cancer Res 14 2008 7861 7870
21. E.A. Perez, M.F. Press, and A.C. Dueck Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005) Breast Cancer Res Treat 138 2013 99 108
22. T.W. Jacobs, A.M. Gown, H. Yaziji, M.J. Barnes, and S.J. Schnitt Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system J Clin Oncol 17 1999 1983 1987
23. G. Sauter, J. Lee, J.M. Bartlett, D.J. Slamon, and M.F. Press Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 27 2009 1323 1333
24. C.H. Tse, H.C. Hwang, and L.C. Goldstein Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy J Clin Oncol 29 2011 4168 4174
25. R.R. Tubbs, J.D. Pettay, P.C. Roche, M.H. Stoler, R.B. Jenkins, and T.M. Grogan Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J Clin Oncol 19 2001 2714 2721
26. F.F. Gao, D.J. Dabbs, K.L. Cooper, and R. Bhargava Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases Am J Clin Pathol 141 2014 102 110
27. J.M. Bartlett, F.M. Campbell, and M. Ibrahim A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay Am J Clin Pathol 135 2011 157 162
28. N. Dybdal, G. Leiberman, and S. Anderson Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab Breast Cancer Res Treat 93 2005 3 11
29. M.E. Vergara-Lluri, N.A. Moatamed, E. Hong, and S.K. Apple High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines Mod Pathol 25 2012 1326 1332
30. R.D. Mass, M.F. Press, and S. Anderson Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 6 2005 240 246
31. E.E. Grimm, R.A. Schmidt, P.E. Swanson, S.M. Dintzis, and K.H. Allison Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases Am J Clin Pathol 134 2010 284 292
32. B.B. Rasmussen, M. Andersson, I.J. Christensen, and S. Moller Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006: a nationwide study including correlation between HER-2 status and other prognostic variables Acta Oncol 47 2008 784 788
33. S. Paik, J. Bryant, and E. Tan-Chiu Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 2002 852 854
34. P.C. Roche, V.J. Suman, and R.B. Jenkins Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J Natl Cancer Inst 94 2002 855 857
35. A.E. McCullough, P. Dell'orto, and M.M. Reinholz Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study Breast Cancer Res Treat 143 2014 485 492
36. C. Denkert, J. Huober, and S. Loibl HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer Breast Cancer Res 15 2013 R11
37. J. Starczynski, N. Atkey, and Y. Connelly HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations Am J Clin Pathol 137 2012 595 605
38. I. Vanden Bempt, P. Van Loo, and M. Drijkoningen Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing J Clin Oncol 26 2008 4869 4874
39. W.M. Hanna, J. Ruschoff, and M. Bilous HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity Mod Pathol 27 2014 4 18
40. Y. Liu, L. Ma, and D. Liu Impact of polysomy 17 on HER2 testing of invasive breast cancer patients Int J Clin Exp Pathol 7 2013 163 173
41. A.D. Watters, J.J. Going, T.G. Cooke, and J.M. Bartlett Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma Breast Cancer Res Treat 77 2003 109 114
42. P.A. Kaufman, G. Broadwater, and K. Lezon-Geyda CALGB 150002: correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC) J Clin Oncol 25 2007 1009
43. L. Downey, R.B. Livingston, and M. Koehler Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer Clin Cancer Res 16 2010 1281 1288
44. E.A. Perez, M.M. Reinholz, and D.W. Hillman HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial J Clin Oncol 28 2010 4307 4315
45. C. Marchio, M.B. Lambros, and P. Gugliotta Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis J Pathol 219 2009 16 24
46. S. Vranic, B. Teruya, S. Repertinger, P. Ulmer, J. Hagenkord, and Z. Gatalica Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17 Cancer 117 2011 48 53
47. C.B. Moelans, R.A. de Weger, and P.J. van Diest Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification Breast Cancer Res Treat 120 2010 1 7
48. Z. Varga, R.R. Tubbs, and Z. Wang Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer Breast Cancer Res Treat 132 2012 925 935
49. B. Bernasconi, A.M. Chiaravalli, G. Finzi, K. Milani, and M.G. Tibiletti Genetic heterogeneity in HER2 testing may influence therapy eligibility Breast Cancer Res Treat 133 2012 161 168
50. G.H. Vance, T.S. Barry, and K.J. Bloom Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines Arch Pathol Lab Med 133 2009 611 612
51. A.I. Bartlett, J. Starcyznski, and T. Robson Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition Am J Clin Pathol 136 2011 266 274
52. H. Seol, H.J. Lee, and Y. Choi Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance Mod Pathol 25 2012 938 948
53. M.C. Chang, J.I. Malowany, J. Mazurkiewicz, and M. Wood "Genetic heterogeneity" in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases Mod Pathol 25 2012 683 688
54. H. Song, T.O. Kim, and S.Y. Ma Intratumoral heterogeneity impacts the response to anti-neu antibody therapy BMC Cancer 14 2014 647
55. H.J. Lee, A.N. Seo, and E.J. Kim HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer Am J Clin Pathol 142 2014 755 766
56. A. Valent, F. Penault-Llorca, A. Cayre, and G. Kroemer Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical management Cancer Genet 206 2013 37 41
57. S. Dawood, K. Broglio, A.U. Buzdar, G.N. Hortobagyi, and S.H. Giordano Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review J Clin Oncol 28 2010 92 98
58. L. Gianni, T. Pienkowski, and Y.H. Im Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol 13 2012 25 32
59. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
60. M. Untch, M. Rezai, and S. Loibl Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study J Clin Oncol 28 2010 2024 2031
61. D. Slamon, W. Eiermann, and N. Robert Adjuvant trastuzumab in HER2-positive breast cancer N Engl J Med 365 2011 1273 1283
62. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
63. L. Zabaglo, O. Stoss, and J. Ruschoff HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab Ann Oncol 24 2013 2761 2766
64. M. Toi, J. Sperinde, and W. Huang Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer BMC Cancer 10 2010 56
65. A. Lipton, W.J. Kostler, and K. Leitzel Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab Cancer 116 2010 5168 5178
66. C. Gomez-Martin, J.C. Plaza, and R. Pazo-Cid Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab J Clin Oncol 31 2013 4445 4452
67. J.W. Kim, J.H. Kim, and S.A. Im HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer Cancer Chemother Pharmacol 72 2013 109 115
68. C. Desmedt, J. Sperinde, and F. Piette Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH Diagn Mol Pathol 18 2009 22 29
69. S. Paik, C. Kim, and N. Wolmark HER2 status and benefit from adjuvant trastuzumab in breast cancer N Engl J Med 358 2008 1409 1411
70. S. Ithimakin, K.C. Day, and F. Malik HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab Cancer Res 73 2013 1635 1646
71. A. Goldhirsch, W.C. Wood, A.S. Coates, R.D. Gelber, B. Thurlimann, and H.J. Senn Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747